AstraZeneca announced that its experimental drug tozorakimab achieved the primary objective in a late-stage clinical trial focused on chronic obstructive pulmonary disease (COPD), demonstrating a reduction in moderate-to-severe exacerbations.
The Phase 3 study, referred to as MIRANDA, assessed the efficacy of tozorakimab in patients who continued to experience significant COPD flare-ups despite being treated with inhaled standard therapies. Within the trial, participants received either a 300 mg dose of tozorakimab or a placebo every two weeks across a one-year treatment period, with both groups continuing their existing standard of care. Over the course of the study, dosing was maintained at regular two-week intervals while patients remained on background therapy. In total, 1,451 patients took part in the study.
Based on the company’s report, treatment with tozorakimab led to a statistically significant and clinically meaningful decline in the annualized rate of moderate-to-severe exacerbations. This reduction was recorded in both current smokers and individuals who had previously smoked, allowing the study to meet both its primary and secondary endpoints. These results further extend findings released in March, when two additional Phase 3 trials also achieved their endpoints by lowering COPD flare-up rates, providing further consistency across multiple late-stage evaluations.
AstraZeneca indicated that the therapy was generally well tolerated throughout the MIRANDA study, and that its safety profile remained consistent with what had been observed in earlier clinical evaluations. The company also noted that tolerability findings aligned with previously recorded data from earlier-stage and late-stage studies. Although the company plans to submit the findings to regulatory authorities, it stated that the detailed data from the study will be disclosed at a future scientific meeting rather than being made publicly available at this stage.
The outcome of the MIRANDA trial represents another positive development for tozorakimab, marking its third successful Phase 3 trial in COPD within the year. These results follow earlier challenges observed in the same class of treatments, where other therapies targeting IL-33 signaling did not meet their intended endpoints in clinical studies, drawing attention to differing outcomes within the same therapeutic approach.
Tozorakimab functions by inhibiting signaling pathways associated with IL-33, a protein involved in inflammatory processes. Its mechanism of action includes blocking both ST2 and RAGE/EGFR signaling pathways, distinguishing it from other therapies in the same category. The RAGE/EGFR pathway is linked to mucus production and epithelial remodeling, processes that contribute to worsening symptoms and reduced lung function in individuals with COPD, and are associated with the progression of the disease.
“These data further demonstrate tozorakimab’s exciting potential as a first-in-class biologic with a truly differentiated mechanism of action that inhibits the signalling of the reduced and oxidised forms of IL-33 to address underlying drivers of COPD,” said Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca.
Barr also stated that the company intends to share the findings with regulatory authorities as well as with the broader scientific community in due course.
Beyond its development in COPD, AstraZeneca is continuing to study tozorakimab across additional indications. The drug is currently being evaluated in a late-stage clinical trial for severe viral lower respiratory tract disease, and it is also under investigation in a Phase 2 trial involving patients with asthma.
What is the MIRANDA Trial?
The MIRANDA trial is a large-scale Phase 3 clinical study conducted by to assess the safety and efficacy of tozorakimab. This investigational monoclonal antibody targets inflammatory pathways associated with COPD exacerbations.
AstraZeneca designed the MIRANDA trial to focus on reducing flare-ups, improving lung function, and enhancing quality of life for patients living with chronic respiratory conditions.
Key Results from AstraZeneca’s MIRANDA Trial
Results from the trial demonstrate that AstraZeneca’s tozorakimab significantly reduced moderate-to-severe COPD exacerbations compared to standard therapies. Patients treated with the drug also showed improvements in respiratory symptoms and overall disease control.
Additionally, AstraZeneca reported a favorable safety profile, with no unexpected adverse events, reinforcing confidence in the therapy’s long-term potential.
Why This Matters for COPD Patients
COPD remains a leading cause of morbidity and mortality worldwide. With limited treatment options for severe cases, AstraZeneca’s breakthrough offers hope for improved disease management.
By targeting underlying inflammation more precisely, AstraZeneca is paving the way for next-generation biologics in respiratory care, potentially transforming how COPD is treated.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
